

Curriculum Vitae

Personal Data

Title: Dr.	Surname: GUBINELLI	Name: EMANUELA
Date of Birth: July 27th, 1969	Place of Birth: ROME	
Registered in MD Registry of (place) ROME with Licence No. M 45708		

Education

Graduation in: Medicine and Surgery	Date: Nov. 1993
Specialty in: Dermatology and Venereology	Date: Nov. 1998

Current Position

Role/Position: Dermatologist
Hospital Dept.: V Dermatologic Unit
Hospital Name and Address: Istituto Dermopatico dell'Immacolata, IDI-IRCCS
Via dei Monti di Creta 104
00100 Roma - Italy

Previous Positions *(summary with dates)*

2006-2019 Responsible of Psoriasis Research Program PSOCARE, sponsored by National Pharmaceutical Agency AIFA, for Istituto Dermopatico dell'Immacolata (IDI-IRCCS), Rome, Italy
2005 - to date Dermatologist c/o Istituto Dermopatico dell'Immacolata (IDI-IRCCS), Rome, Italy.
2000- 2004 Fellowship c/o Istituto Dermopatico dell'Immacolata (IDI-IRCCS), Rome, Italy.

Clinical Trials & Studies Experience

<p>2003 Co-Investigator: “A phase III, multicenter, randomized, double-blind, placebo-controlled trial to determine the efficacy and the safety of infliximab induction therapy followed by multiple regimens of maintenance in the treatment of patients with plaque psoriasis. (C0168T44)</p> <p><i>CENTOCOR</i></p>
<p>2004 Co-Investigator: “A multicenter, open-label, phase IIIb / IV trial with efalizumab administered subcutaneously in adult patients with moderate to severe chronic plaque psoriasis, unresponsive or for which there is a contraindication to, or are intolerant to other systemic therapies including cyclosporine, methotrexate and PUVA”</p> <p><i>SERONO</i></p>
<p>2004 Co-Investigator “Clinical study on tacrolimus ointment over the long-term. “Control study-Adults”.</p> <p><i>Yamanouchi Europe/Fujisawa GmbH</i></p>
<p>2007 Co-Investigator “A randomized, preliminary, open trial, to evaluate the efficacy of etanercept 50 mg once a week for 24 weeks, of etanercept 50 mg twice weekly for 12 weeks with subsequent reduction to etanercept 50 mg once a week for 12 weeks, on nail and skin symptoms in patients with nail psoriasis and psoriasis plaques.</p> <p><i>Wyeth Lederle Spa</i></p>
<p>2007 Principal Investigator: “ Study of predictive factors of response to treatment with efalizumab in psoriasis patients.</p> <p><i>IDI-IRCCS</i></p>
<p>2007 Co-Investigator: “ A phase III, multicenter, randomized, double-blind, double-placebo, to compare the efficacy and the safety of treatment with azithromycin microspheres, powder for oral suspension, 2 g, a single weekly administration for 8 weeks and treatment with capsules minocycline 100 mg daily for 8 weeks in outpatients with moderate to severe inflammatory acne”.</p> <p><i>PFIZER ITALIA</i></p>
<p>2009 Co-Investigator: “A randomized, double-blind, placebo-controlled study on the use of benzydamine cream in patients with plaque psoriasis: validation of rational and titration of the”.</p> <p><i>ANGELINI FARMACEUTICI</i></p>
<p>2009 Co-Investigator: “Observational study on rebound events and relapse of psoriasis (time to relapse) after completion of therapy with etanercept solution for injection (25 mg / 50 mg)</p> <p><i>IDI-IRCCS</i></p>
<p>2014 Co-Investigator: Studio multicentrico, prospettico, della durata di 24 settimane per valutare il tasso di risposta clinica PASI 90 e il profilo di sicurezza di secukinumab 300 mg in pazienti Cw6-negativi e Cw6-positivi con psoriasi a placche cronica da moderata a severa (SUPREME).</p> <p><i>NOVARTIS</i></p>

PUBLICATIONS

1. Menaguale G, Gradoni L, Melchi CF, Gubinelli E, Pianosi G, Tonanzi T, Fazio M. "Leishmaniosi della lingua: osservazioni a proposito di un caso" *Esperienze Dermatologiche*, Vol IV (n1) gennaio 2002:1-4.
2. Gubinelli E, Posteraro P, Girolomoni G. Idiopathic CD4+ T lymphocytopenia associated with disseminated flat warts and alopecia areata. *J Dermatol* 29:653-656, 2002.
3. Gubinelli E, Cocuroccia B, Lazzarotto T, Girolomoni G. Nodular perianal herpes simplex with prominent plasma cell infiltration. *Sex Transm Dis* 30:157-159, 2003.
4. Cocuroccia B, Gaido J, Gubinelli E, Annessi G, Girolomoni G. Localized cutaneous hyalohyphomycosis caused by a *Fusarium* species infection in a renal transplant patient. *J Clin Microbiol* 41:905-907, 2003.
5. Gubinelli E, Cocuroccia B, Girolomoni G. Subacute cutaneous lupus erythematosus induced by nifedipine *J Cutan Med Surg* 7:243-246, 2003.
6. Cocuroccia B, Gubinelli E, Fazio M, Girolomoni G. Primary cutaneous actinomycosis of the forehead. *J Eur Acad Dermatol Venereol* 17:331-333, 2003.
7. Gubinelli E, Posteraro P, Cocuroccia B, Girolomoni G. Epidermodysplasia verruciformis with multiple mucosal carcinomas treated with pegylated interferon alfa and acitretin. *J Dermatolog Treat* 14:184-188, 2003.
8. Gubinelli E, Cocuroccia B, Fazio M, Annessi G, Girolomoni G. Papular neutrophilic dermatosis and erythema elevatum diutinum following erythropoietin therapy in a patient with myelodysplastic syndrome. *Acta Derm Venereol* 83:358-361, 2003.
9. Gisondi P, Perez M, Gubinelli E, Cocuroccia B, Fazio M, Girolomoni G. Disseminated lupus vulgaris. *Eur J Dermatol* 13:500-502, 2003.
10. Cocuroccia B, Gubinelli E, Gisondi P, Girolomoni G. Lebbra lepromatosa. *Derm Clin* 23:137-140, 2003.

11. Gisondi P, Gubinelli E, Cocuroccia B, Girolomoni G. Targeting tumor necrosis factor-alpha in the therapy of psoriasis. *Curr Drug Targets Inflamm Allergy*. 2004 Jun ;3(2):175-83. Review
12. Sansbury JC, Cocuroccia B, Jorizzo JL, Gubinelli E, Gisondi P, Girolomoni G. Treatment of recalcitrant scleromyxedema with thalidomide in 3 patients. *J Am Acad Dermatol* 51:126-131, 2004.
13. Cocuroccia B, Gubinelli E, Gisondi P, Girolomoni G. An itchy vesiculobullous eruption in a patient with chronic lymphocytic leukaemia. *Int J Clin Pract*. 2004 Dec;58(12):1177-9.
14. Gisondi P, Cocuroccia A, Gubinelli E, Girolomoni G. Squamous cell carcinoma arising in lupus vulgaris. *G Ital Dermatol Venereol* 00:000-000, 2004.
15. Terrinoni A, Cocuroccia B, Gubinelli E, Zambruno G, Candi E, Melino J, Girolomoni G. Identification of the keratin K9 R162W mutation in patients of Italian origin with epidermolytic palmoplantar keratoderma. *Eur J Dermatol*. 2004 Nov-Dec;14(6):375-8.
16. Cocuroccia B, Gubinelli E, Zambruno G, Girolomoni G. Persistent unilateral orbital and eyelid oedema as a manifestation of Melkersson-Rosenthal syndrome. *J Eur Acad Dermatol Venereol*. 2005 Jan;19(1):107-11.
17. Gubinelli E, Fiorentini S, Cocuroccia B, Girolomoni G. Yellow nail syndrome associated with sleep apnoea. *J Eur Acad Dermatol Venereol*. 2005 Sep;19(5):650-1.
18. Cocuroccia B, Gubinelli E, Gisondi P, Girolomoni G. Autoimmune progesterone dermatitis. *Gynecol Endocrinol*. 2006 Jan;22(1):54-6.
19. Gubinelli E, Bergamo F, Didona B, Annessi G, Atzori F, Raskovic D. Pemphigus foliaceus treated with etanercept. *J Am Acad Dermatol*. 2006 Dec;55(6):1107-8.
20. Gubinelli E, Canzona F, Tonanzi T, Raskovic D, Didona B. Toxic epidermal necrolysis successfully treated with etanercept. *J Dermatol* 2009 Mar;36(3):150-3.
21. Saveria Pastore, Emanuela Gubinelli, Luca Leoni, Desanka Raskovic, and Liudmila Korkina. Biological drugs targeting the immune response in the therapy of psoriasis. *Biologics*. 2008 December; 2(4): 687–697.

22. Gubinelli E, Angelo C, Pacifico V. A case of dystrophic epidermolysis bullosa improved with etanercept for concomitant psoriasis arthritis. *Am J Clin Dermatol*. 2010;11 Suppl 1:53-4.
23. Pastore S, Mariani V, Lulli D, Gubinelli E, Raskovic D, Mariani S, Stancato A, De Luca C, Pecorelli A, Valacchi G, Potapovich AI, Kostyuk VA, Korkina LG. Glutathione peroxidase activity in the blood cells of psoriatic patients correlates with their responsiveness to Efalizumab. *Free Radic Res* 2011 Feb 16.
24. Gisondi P, Cazzaniga S, Chimenti S, Giannetti A, MacCarone M, Picardo M, Girolomoni G, Naldi L; Psocare Study Group. Metabolic abnormalities associated with initiation of systemic treatment for psoriasis: evidence from the Italian Psocare Registry. *J Eur Acad Dermatol Venereol* 2013 Jan; 27(1):e30-41.
25. Laurenti R, Giovannangeli F, Gubinelli E, Viviano MT, Errico A, Leoni L, Ballanti E, Migliore A. Long-term safety of anti-TNF adalimumab in HBc antibody-positive psoriatic arthritis patients: a retrospective case series of 8 patients. *Clin Dev Immunol*. 2013;2013:41.
26. Piaserico S, Cazzaniga S, Chimenti S, Giannetti A, MacCarone M, Picardo M, Peserico A, Naldi L; Psocare Study Group. Efficacy of switching between tumor necrosis factor- α inhibitors in psoriasis: results from the Italian Psocare registry. *J Am Acad Dermatol*. 2014 Feb;70(2):257-62.
27. Tabolli S, Paradisi A, Giannantoni P, Gubinelli E, Abeni D. Factors associated with the prescription of "traditional" or "biological" systemic treatment in psoriasis. *J Dermatolog Treat*. 2015 feb;26(1):37-40.
28. Gisondi P, Cazzaniga S, Chimenti S, MacCarone M, Picardo M, Girolomoni G, Naldi L; Psocare Study Group. Latent tuberculosis infection in patients with chronic plaque psoriasis: evidence from the Italian Psocare Registry. *Br J Dermatol*. 2015 Jun;172(6):1613-20.
29. Mercurio L, Morelli M, Scarponi C, Eisenmesser EZ, Doti N, Pagnanelli G, Gubinelli E, Mazzanti C, Cavani A, Ruvo M, Dinarello CA, Albanesi C, Madonna S. IL-38 has an anti-inflammatory action in psoriasis and its expression correlates with disease severity and therapeutic response to anti-IL-17A treatment. *Cell Death Dis*. 2018 Oct 30;9(11):1104.
30. Sampogna F, Mastroeni S, Pallotta S, Gubinelli E, Teofili P, Fusari R, Uras C, Quinto RM, Napolitano M, Abeni D. General health status in psoriasis patients, as assessed by the 12-item Short Form (SF-12) Health Survey, is poorly associated with Psoriasis Area Severity Index. *J Eur Acad Dermatol Venereol*. 2019 Jun;33(6):233-235

REVIEWS

1. Gisoni P, Gubinelli E, Cocuroccia B, Girolomoni G. Targeting tumor necrosis factor in the therapy of psoriasis. *Curr Drug Targets Inflamm Allergy* 3:175-183, 2004.

2. Gubinelli E, Cocuroccia B, Gisoni P, Girolomoni G. La dermatite atopica. *Prospet Pediatria* 34:127-138, 2004.

BOOK CHAPTERS

Girolomoni G, Gisoni P, Cocuroccia B, Gubinelli E. Dermatite atopica. In: *Dermatologia Basata sulle Prove di Efficacia*. Naldi L, Rebora A, Liberati A, Eds. Masson, Milano. Pag 000-000, 2005.

I hereby authorize the processingof my personal data above, pursuant to Italian law 196/2003 on Confidentiality and consent to their transfer torelated companies, other companies hired byto collect, process or store data in connection with a study, and to the Food and Drug Administration (FDA) in the USA and any companies hired by the FDA to collect, process or store such data. I understand that these data could be transferred to other countries, including the USA, where the data protection laws may not provide the same protection as the Italian Law.

Date 13.11.2019